Home > News > NanoNovus: January 13, 2006
January 16th, 2006
Abstract:
Jack Uldrich: Today was a big day in the field of nanotech investing. Elan announced a licensing agreement with EntreMed that grants the company the right to utilize Elan's (NYSE: ELN) proprietary NanoCrystal technology. I have long been bullish on this technology and it is why I recommended Elan ... after it dropped to around $3 a share this past spring. (two more recommendations follow)
Source:
NanoNovus
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||